REGN · Healthcare
What a holder would want to know before buying REGN: where the price sits in its own history, how far it has fallen before and whether it recovered, and what the business behind it earns. All of it is arithmetic over free market data — no opinions, no recommendations.
Today’s price is 34% above the lowest point of the past year and 12% below the highest.
Over the past year it was cheaper than today on 50% of days and more expensive on 50%. Over the last 10 years: cheaper on 78% of days.
1% above its average price of the last 200 trading days.
Fell 20% or more 7 times in 10 years. The deepest fall was 60%; the longest took 2.8 years to get back to its peak. 6 of 7 have recovered so far.
It is in one now: 38% below the Aug 2024 peak.
Regeneron Pharmaceuticals, Inc. · Healthcare · Biotechnology · a large company worth $76.86B
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and…
revenue profit
Sales of $14.34B in 2025, with $4.50B of profit. Sales grew in 3 of the last 3 years.
Keeps about 28 cents of every dollar of sales as profit.
Generates more free cash in a year ($3.07B) than it owes in total ($2.71B).
You pay $18 for every $1 of last year’s profit, and $12 for every $1 of profit expected next year.
A high number means buyers expect growth; a low one means they expect little, or fear trouble. Large US companies have averaged roughly 15–20 over the decades.
Pays 0.51% a year in dividends at today’s price · next ex-dividend Aug 18.
27 analysts: 18 say buy, 8 hold, 1 sell. Their average 12-month target is $859.04 (range $730.00–$1,030.00).
Insiders made 0 purchases and 6 sales in the last 6 months. Executives routinely sell shares they were paid in; buying with their own money is the rarer signal.
Free data from Yahoo Finance, refreshed daily. This is evidence about the business and its price history, not a recommendation.
Poshkan is paper trading: real prices, virtual money. Buy REGN with $10,000 that isn’t real, set a stop before you enter, and find out what your idea would actually have done.
Data from Yahoo Finance, refreshed hourly. Nothing here is financial advice. Poshkan is a paper-trading simulator — all money, trades and returns are virtual.